Gadd quits Pfizer to take up British Biotech position

Pharmaceutical giant British Biotech, which develops drugs to fight diseases such as cancer, has named Alison Gadd as head of regulatory affairs.

Gadd takes responsibility for British Biotech's relationships with regulatory agencies across the world, focusing on the UK, Europe and the US.

The news comes as the company confirmed it is to change its name by the end of the year in a bid to reinvent itself.

British Biotech, which had a number of drug failures during clinical trials in the mid-1990s, has recently suffered a depressed share-price, hitting an all-time low last month.

Gadd joins from Pfizer, where she was global head of anti-viral compounds.

Prior to Pfizer, Gadd - a PhD pharmacologist - worked as chief of European and UK regulatory groups at the then HMR, now part of Franco-German pharmaceutical group Aventis.

British Biotech researches and develops drugs to help fight diseases with limited treatment options.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in